HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deberdt, W. G. Articles by Breier, A. Search for Related Content PubMed PubMed Citation Articles by Deberdt, W. G. Articles by Breier, A.

Comparison of Olanzapine and Risperidone in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients With Dementia

Received August 20, 2003; revised April 8, July 27, 2004; accepted August 10, 2004. From Lilly Research Laboratories, Indianapolis, IN (WGD, PDF, CAY, DPH, DLL, EKD, AB), the Geriatric Research, Education and Clinical Center Program, Veterans Affairs Medical Center; Minneapolis, MN (MWD), Agewell® Ltd., Indianapolis, IN (SAR), and Eli Lilly G.m.b.H., Vienna, Austria (MD). Send correspondence and reprint requests to Dr. Walter G. Deberdt, Lilly, Stoofstraat 52, 1000 Brussels, Belgium. e-mail: deberdt_walter{at}lilly.com
© 2005 American Association for Geriatric Psychiatry

Objective: The authors compared efficacy of olanzapine versus placebo and risperidone as measured by the Neuropsychiatric Inventory and Clinical Global Impression–Severity of Psychosis scale in patients with dementia-related psychosis. Methods: Patients with moderate-to-severe psychotic symptoms associated with dementia were recruited from outpatient or residential settings and randomly assigned to 10-week, double-blind, flexible-dose treatment with olanzapine (N=204; 2.5 mg–10 mg/day; mean: 5.2 mg/day), risperidone (N=196; 0.5 mg–2 mg/day; mean: 1.0 mg/day) or placebo (N=94). Results: Most measures of neuropsychiatric functioning improved in all treatment groups, including the placebo group, and no significant treatment differences occurred. Overall discontinuation was lowest in the placebo group, and the olanzapine group had a significantly higher incidence of discontinuation due to adverse events (16.2%) relative to placebo (3.2%) and risperidone (8.7%) groups. Treatment-emergent extrapyramidal symptoms were more numerous for risperidone- than placebo- or olanzapine-treated patients. Abnormally high prolactin levels occurred in 78.0% of risperidone patients, compared with 16.7% for olanzapine and 5.0% for placebo. The incidence of weight gain greater than 7% from baseline was higher in the olanzapine group relative to risperidone, but neither active-treatment group showed a statistical difference from placebo (1.1%). No other statistically significant and clinically relevant differences were seen for any other vital sign, electrocardiographic measure, or laboratory hematology and chemistry, including glucose, except for cholesterol, which decreased from baseline to endpoint in both active-treatment groups. Conclusions: Patients’ neuropsychiatric functioning improved with olanzapine, risperidone, and placebo treatment. There was a substantial response in the placebo group, and no significant differences emerged among treatments.

Key Words: Dementia • Psychosis • Behavioral Disturbances • Neuroleptics

This article has been cited by other articles:

				J. E. Streim, A. P. Porsteinsson, C. D. Breder, R. Swanink, R. Marcus, R. McQuade, and W. H. Carson A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole for the Treatment of Psychosis in Nursing Home Patients with Alzheimer Disease Am J Geriatr Psychiatry, July 1, 2008; 16(7): 537 - 550. [Abstract] [Full Text] [PDF]

				I. Lipkovich, J. Ahl, R. Nichols, T. Hardy, and V. Poole Hoffmann Weight Changes During Treatment With Olanzapine in Older Adult Patients With Dementia and Behavioral Disturbances J Geriatr Psychiatry Neurol, June 1, 2007; 20(2): 107 - 114. [Abstract] [PDF]

				A. T. Blaszczyk and M. Mathys Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia Journal of Pharmacy Practice, February 1, 2007; 20(1): 13 - 28. [Abstract] [PDF]

				J. H. Friedman Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning. Neurology, August 22, 2006; 67(4): 564 - 566. [Abstract] [Full Text] [PDF]

				J. H. Friedman Anticholinergics in Dementia and Other Confounding Problems Am J Geriatr Psychiatry, April 1, 2006; 14(4): 384 - 384. [Full Text] [PDF]

				W. Deberdt Author's Response to Friedman Am J Geriatr Psychiatry, April 1, 2006; 14(4): 384 - 385. [Full Text] [PDF]

				J. H. Friedman Atypical antipsychotics have very different adverse effect profiles and should not be lumped together. Arch Intern Med, March 13, 2006; 166(5): 586 - 586. [Full Text] [PDF]

				L. S. Schneider, K. Dagerman, and P. S. Insel Efficacy and Adverse Effects of Atypical Antipsychotics for Dementia: Meta-analysis of Randomized, Placebo-Controlled Trials Am J Geriatr Psychiatry, March 1, 2006; 14(3): 191 - 210. [Abstract] [Full Text] [PDF]